Brokerages forecast that Glaukos Corp (NYSE:GKOS) will report sales of $40.71 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Glaukos’ earnings. The lowest sales estimate is $39.80 million and the highest is $41.23 million. Glaukos reported sales of $33.17 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 22.7%. The firm is expected to issue its next quarterly earnings results after the market closes on Wednesday, February 28th.
According to Zacks, analysts expect that Glaukos will report full year sales of $40.71 million for the current year, with estimates ranging from $157.70 million to $159.00 million. For the next financial year, analysts expect that the business will report sales of $174.12 million per share, with estimates ranging from $168.50 million to $185.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Glaukos.
A number of research firms have weighed in on GKOS. BMO Capital Markets restated a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. Cantor Fitzgerald set a $48.00 price target on Glaukos and gave the company a “buy” rating in a research note on Wednesday, January 10th. Zacks Investment Research cut Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 13th. ValuEngine cut Glaukos from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Finally, Stephens restated an “overweight” rating and issued a $40.00 price target (down from $47.00) on shares of Glaukos in a research note on Monday, November 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $44.86.
Several institutional investors and hedge funds have recently bought and sold shares of GKOS. Teachers Advisors LLC increased its position in shares of Glaukos by 74.8% during the second quarter. Teachers Advisors LLC now owns 51,598 shares of the medical instruments supplier’s stock worth $2,140,000 after purchasing an additional 22,086 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Glaukos by 13.9% during the second quarter. Ameriprise Financial Inc. now owns 103,507 shares of the medical instruments supplier’s stock worth $4,292,000 after purchasing an additional 12,613 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new stake in shares of Glaukos during the second quarter worth about $274,000. Northern Trust Corp increased its position in shares of Glaukos by 15.1% during the second quarter. Northern Trust Corp now owns 251,342 shares of the medical instruments supplier’s stock worth $10,424,000 after purchasing an additional 33,017 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Glaukos by 3.4% during the second quarter. Vanguard Group Inc. now owns 1,668,345 shares of the medical instruments supplier’s stock worth $69,187,000 after purchasing an additional 55,507 shares in the last quarter.
Glaukos (NYSE GKOS) opened at $31.07 on Tuesday. The stock has a market capitalization of $1,073.95, a price-to-earnings ratio of 258.92, a P/E/G ratio of 45.03 and a beta of 1.21. Glaukos has a fifty-two week low of $23.08 and a fifty-two week high of $52.49.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.